Grace Therapeutics Inc. (GRCE)
3.52
-0.39 (-9.97%)
At close: Jan 14, 2025, 3:58 PM
3.50
-0.71%
After-hours Jan 14, 2025, 06:56 PM EST
undefined% (undefined)
| Bid | 3.5 |
| Market Cap | 35.74M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.29 |
| PE Ratio (ttm) | -2.73 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 4.1 |
| Volume | 57,149 |
| Avg. Volume (20D) | 63,447 |
| Open | 3.88 |
| Previous Close | 3.91 |
| Day's Range | 3.50 - 4.07 |
| 52-Week Range | 1.98 - 4.97 |
| Beta | undefined |
About GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2012
Employees 4
Stock Exchange NASDAQ
Ticker Symbol GRCE
Website https://www.acastipharma.com